Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)

Abstract

The aim of this prospective study was to evaluate the long-term efficacy and safety of hydroxyurea (HU) in patients with sickle cell disease (SCD). Thirty-four patients with sickle cell anemia (hemoglobin S [HbS]/HbS), 131 with HbS/β0-thal, and 165 with HbS/β+-thal participated in this trial. HU was administered to 131 patients, whereas 199 patients were conventionally treated. The median follow-up period was 8 years for HU patients and 5 years for non-HU patients. HU produced a dramatic reduction in the frequency of severe painful crises, transfusion requirements, hospital admissions, and incidence of acute chest syndrome. The probability of 10-year survival was 86% and 65% for HU and non-HU patients, respectively (P = .001), although HU patients had more severe forms of SCD. The 10-year probability of survival for HbS/HbS, HbS/β 0-thal, and HbS/IVSI-110 patients was 100%, 87%, and 82%, respectively, for HU patients and 10%, 54%, and 66%, for non-HU patients. The multivariate analysis showed that fetal hemoglobin values at baseline and percentage change of lactate dehydrogenase between baseline and 6 months were independently predicted for survival in the HU group. These results highlight the beneficial effect of HU, which seems to modify the natural history of SCD and raise the issue of expanding its use in all SCD patients.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2009-05-221333

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 41 references

Cited by

See all 446

Metadata

Authors
Voskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulou, A., Loukopoulos, D., & Terpos, E.
Affiliations
  • Laiko General Hospital of Athens (GR)
  • National and Kapodistrian University of Athens (GR)
  • General Hospital of Athens G. Genimatas (GR)
  • Academy of Athens (GR)
Venue
Blood
Published
2010-03-25
Volume
115
Issue
12
Pages
2354-2363
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2074858698
Cited by
430
References
41
Citations by year
2026: 14 · 2025: 20 · 2024: 17 · 2023: 27 · 2022: 24 · 2021: 25 · 2020: 32 · 2019: 30 · 2018: 24 · 2017: 31 · 2016: 33 · 2015: 42 · 2014: 26 · 2013: 18 · 2012: 20
FWCI
10.61
Type
journal article
Language
en
Open access
closed
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
  • Health Sciences › Medicine › Hematology › Blood groups and transfusion
  • Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
Keywords
hydroxyurea, sickle cell disease, beta-thalassemia, long-term efficacy and safety, survival, acute chest syndrome, vaso-occlusive crisis, transfusion requirements, fetal hemoglobin, lactate dehydrogenase, natural history of disease
MeSH terms
Adult, Aged, Anemia, Sickle Cell, Antisickling Agents, Blood Transfusion, Female, Fetal Hemoglobin, Follow-Up Studies, Hemoglobin, Sickle, Hospitalization, Humans, Hydroxyurea, Male, Middle Aged, Morbidity, Predictive Value of Tests, Prospective Studies, Time Factors, Multivariate Analysis, Survival Analysis, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). https://app.cochat.ai/papers/10.1182/blood-2009-05-221333
The paper
Voskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulou, A., Loukopoulos, D., & Terpos, E. (2010). The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. https://doi.org/10.1182/blood-2009-05-221333

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.